rs77331749
Positions:
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4BS2
The NM_000238.4(KCNH2):c.2738C>T(p.Ala913Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000522 in 1,524,188 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00051 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00052 ( 1 hom. )
Consequence
KCNH2
NM_000238.4 missense
NM_000238.4 missense
Scores
1
6
12
Clinical Significance
Conservation
PhyloP100: 0.134
Genes affected
KCNH2 (HGNC:6251): (potassium voltage-gated channel subfamily H member 2) This gene encodes a component of a voltage-activated potassium channel found in cardiac muscle, nerve cells, and microglia. Four copies of this protein interact with one copy of the KCNE2 protein to form a functional potassium channel. Mutations in this gene can cause long QT syndrome type 2 (LQT2). Transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, May 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -5 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.37117094).
BS2
High AC in GnomAd4 at 78 AD,Digenic gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
KCNH2 | NM_000238.4 | c.2738C>T | p.Ala913Val | missense_variant | 12/15 | ENST00000262186.10 | NP_000229.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
KCNH2 | ENST00000262186.10 | c.2738C>T | p.Ala913Val | missense_variant | 12/15 | 1 | NM_000238.4 | ENSP00000262186 | P1 | |
KCNH2 | ENST00000330883.9 | c.1718C>T | p.Ala573Val | missense_variant | 8/11 | 1 | ENSP00000328531 | |||
KCNH2 | ENST00000684241.1 | n.3571C>T | non_coding_transcript_exon_variant | 10/13 |
Frequencies
GnomAD3 genomes AF: 0.000513 AC: 78AN: 152104Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
78
AN:
152104
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000400 AC: 48AN: 120030Hom.: 1 AF XY: 0.000411 AC XY: 27AN XY: 65760
GnomAD3 exomes
AF:
AC:
48
AN:
120030
Hom.:
AF XY:
AC XY:
27
AN XY:
65760
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000523 AC: 717AN: 1372084Hom.: 1 Cov.: 36 AF XY: 0.000534 AC XY: 361AN XY: 676160
GnomAD4 exome
AF:
AC:
717
AN:
1372084
Hom.:
Cov.:
36
AF XY:
AC XY:
361
AN XY:
676160
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000513 AC: 78AN: 152104Hom.: 0 Cov.: 33 AF XY: 0.000592 AC XY: 44AN XY: 74290
GnomAD4 genome
AF:
AC:
78
AN:
152104
Hom.:
Cov.:
33
AF XY:
AC XY:
44
AN XY:
74290
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:3Uncertain:5Benign:5Other:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Long QT syndrome 2 Pathogenic:2Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | May 02, 2023 | The KCNH2 c.2738C>T (p.Ala913Val) is a missense variant that has been reported in seven studies in which it is found in a heterozygous state in a total of eleven individuals with either confirmed or suspected long QT syndrome (Tester et al. 2005; Vatta et al. 2006; Kapplinger et al. 2009; Lieve et al. 2013; Trolle et al. 2013; Christiansen et al. 2014; Webster et al. 2019). The p.Ala913Val variant was also detected in a compound heterozygous state in one individual with long QT syndrome who also carried a missense variant in the SCN5A gene. This individual's unaffected father and unaffected sibling also carried the p.Ala913Val variant in a heterozygous state (Hoshi et al. 2015). An individual with atrial fibrillation and mitral valve regurgitation was also reported to be heterozygous for the variant (Gregers et al. 2017). The p.Ala913Val variant was absent from 2,964 control chromosomes (Kapplinger et al. 2009; Christiansen et al. 2014) but is reported at a frequency of 0.002390 in the European (Finnish) population of the Genome Aggregation Database, which includes one homozygote. When the KCNH2 protein bearing the p.Ala913Val variant was expressed in HEK293 cells, electrophysiological measurements showed that there was a 37% reduction in the tail current when compared to wildtype protein. The authors stated that this variant alone was not sufficient to cause long QT syndrome (Hoshi et al. 2015). Gregers et al. (2017) performed similar studies indicating that the variant resulted in a mild gain of function rather than a loss of function. Based on the collective evidence and the application of ACMG criteria, the p.Ala913Val variant is classified as a variant of uncertain significance for long QT syndrome. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Nov 14, 2006 | - - |
Likely pathogenic, flagged submission | clinical testing | Blueprint Genetics | Apr 30, 2015 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Center For Human Genetics And Laboratory Diagnostics, Dr. Klein, Dr. Rost And Colleagues | Nov 15, 2017 | - - |
not provided Uncertain:2Benign:2
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Dec 08, 2020 | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Reported in ClinVar with conflicting classifications (ClinVar Variant ID# 14443; Landrum et al., 2016); This variant is associated with the following publications: (PMID: 19716085, 24606995, 22245016, 17060380, 26746457, 30704477, 31395126, 25417810, 26213684, 23936059, 26383259, 15840476, 23631430, 14661677, 16540748, 28416588, 32048431, 31737537) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 09, 2016 | Variant summary: The KCNH2 c.2738C>T (p.Ala913Val) variant is located in the C-terminus causing a missense change involving a non-conserved nucleotide with 3/4 in silico tools (SNPs&GO not captured due to low reliability index) predict a benign outcome for this variant. The variant of interest was not found in controls (ExAC, ESP, 1000 Gs, or publication controls). Multiple publications cite the variant in affected individuals including the variant to co-occur with a known CAV3 mutation, T78M, along with another KCNH2 variant, S654V (not yet scored), along with evidence for lack of cosegregation within one family (Hoshi_2015). Functional studies have implicated that the variant has a mild affect on wild type function (Hoshi_2015), along with the authors further suggested that the variant alone does not cause disease (Hoshi_2015). In addition, a recent independent study performed by Van Driest_2016, in which expert reviews were performed by three independent clinical laboratories to assess classification of this variant, two out of the three laboratories indicated the variant to not be pathogenic. Furthermore, multiple reputable clinical laboratories have provided conflicting classifications, "uncertain significance," "likely pathogenic," or "pathogenic." Therefore, until additional information becomes available, the variant of interest has been classified as a "Variant of Uncertain Significance (VUS)." - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Aug 01, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Jan 20, 2021 | The KCNH2 c.2738C>T; p.Ala913Val variant (rs77331749) is reported in the literature in several individuals affected with long QT syndrome (Hoshi 2015, Kapplinger 2009, Tester 2005, Vatta 2006). This variant is found in the Finnish European population with an overall allele frequency of 0.24% (22/9204 alleles, including one homozygote) in the Genome Aggregation Database. The alanine at codon 913 is moderately conserved, and computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.502). Functional studies indicate a modestly reduced current of the variant protein compared to wildtype, although it is uncertain if this difference is clinically significant (Hoshi 2015). Although the population frequency of this variant is inconsistent with disease, since a low penetrance effect cannot be ruled out, the clinical significance of the p.Ala913Val variant is uncertain at this time. References: Hoshi M et al. Polygenic Case of Long QT Syndrome Confirmed through Functional Characterization Informs the Interpretation of Genetic Screening Results. HeartRhythm Case Rep. 2015 Jul 1;1(4):201-205. Kapplinger JD et al. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm. 2009 Sep;6(9):1297-303. Tester DJ et al. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm. 2005 May;2(5):507-17. Vatta M et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation. 2006 Nov 14;114(20):2104-12. - |
Long QT syndrome Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute | Jan 27, 2017 | - - |
Long QT syndrome 2/9, digenic Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Nov 14, 2006 | - - |
Cardiovascular phenotype Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 02, 2023 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Cardiac arrhythmia Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Apr 14, 2018 | - - |
Congenital long QT syndrome Other:1
not provided, no classification provided | literature only | Cardiovascular Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust | - | This variant has been reported as associated with Long QT syndrome in the following publications (PMID:15840476;PMID:19716085). This is a literature report, and does not necessarily reflect the clinical interpretation of the Imperial College / Royal Brompton Cardiovascular Genetics laboratory. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Uncertain
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
.;T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T;T
M_CAP
Uncertain
D
MetaRNN
Benign
T;T
MetaSVM
Uncertain
D
MutationAssessor
Benign
.;N
MutationTaster
Benign
A;A;A
PrimateAI
Uncertain
T
PROVEAN
Benign
N;N
REVEL
Uncertain
Sift
Benign
T;T
Sift4G
Benign
T;T
Polyphen
B;B
Vest4
MutPred
0.77
.;Loss of relative solvent accessibility (P = 0.0071);
MVP
MPC
0.17
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at